Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.

Sharma P, Barlow WE, Godwin AK, Parkes EE, Knight LA, Walker SM, Kennedy RD, Harkin DP, Logan GE, Steele CJ, Lambe SM, Badve S, Gökmen-Polar Y, Pathak HB, Isakova K, Linden HM, Porter P, Pusztai L, Thompson AM, Tripathy D, Hortobagyi GN, Hayes DF.

J Clin Oncol. 2019 Dec 20;37(36):3484-3492. doi: 10.1200/JCO.19.00693. Epub 2019 Oct 28.

PMID:
31657982
2.

Test-Retest Reproducibility of 18F-FDG PET/CT Uptake in Cancer Patients Within a Qualified and Calibrated Local Network.

Kurland BF, Peterson LM, Shields AT, Lee JH, Byrd DW, Novakova-Jiresova A, Muzi M, Specht JM, Mankoff DA, Linden HM, Kinahan PE.

J Nucl Med. 2019 May;60(5):608-614. doi: 10.2967/jnumed.118.209544. Epub 2018 Oct 25.

3.

Correction to: a Phase 2 Study of 16α-[18F]-Fluoro-17β-Estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC).

Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, Eary JF, Porter P, Shankar LK, Mankoff DA, Linden HM.

Mol Imaging Biol. 2019 Feb;21(1):191. doi: 10.1007/s11307-018-1287-7.

PMID:
30324461
4.

Clinical Potential of Estrogen and Progesterone Receptor Imaging.

Linden HM, Peterson LM, Fowler AM.

PET Clin. 2018 Jul;13(3):415-422. doi: 10.1016/j.cpet.2018.02.005. Review.

5.

The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective.

Press RH, Shu HG, Shim H, Mountz JM, Kurland BF, Wahl RL, Jones EF, Hylton NM, Gerstner ER, Nordstrom RJ, Henderson L, Kurdziel KA, Vikram B, Jacobs MA, Holdhoff M, Taylor E, Jaffray DA, Schwartz LH, Mankoff DA, Kinahan PE, Linden HM, Lambin P, Dilling TJ, Rubin DL, Hadjiiski L, Buatti JM.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1219-1235. doi: 10.1016/j.ijrobp.2018.06.023. Epub 2018 Jun 30. Review.

6.

Prospective Study of Serial 18F-FDG PET and 18F-Fluoride PET to Predict Time to Skeletal-Related Events, Time to Progression, and Survival in Patients with Bone-Dominant Metastatic Breast Cancer.

Peterson LM, O'Sullivan J, Wu QV, Novakova-Jiresova A, Jenkins I, Lee JH, Shields A, Montgomery S, Linden HM, Gralow J, Gadi VK, Muzi M, Kinahan P, Mankoff D, Specht JM.

J Nucl Med. 2018 Dec;59(12):1823-1830. doi: 10.2967/jnumed.118.211102. Epub 2018 May 10.

7.

FDG PET and FES PET Predict PFS on Endocrine Therapy-Response.

Kurland BF, Peterson LM, Linden HM, Mankoff DA.

Clin Cancer Res. 2018 Jan 1;24(1):249-250. doi: 10.1158/1078-0432.CCR-17-2980. No abstract available.

8.

Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).

Sharma P, Barlow WE, Godwin AK, Pathak H, Isakova K, Williams D, Timms KM, Hartman AR, Wenstrup RJ, Linden HM, Tripathy D, Hortobagyi GN, Hayes DF.

Ann Oncol. 2018 Mar 1;29(3):654-660. doi: 10.1093/annonc/mdx821.

9.

Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer.

Chang AE, Wu QV, Jenkins IC, Specht JM, Gadi VK, Gralow JR, Salazar LG, Kurland BF, Linden HM.

Clin Breast Cancer. 2018 Feb;18(1):e143-e149. doi: 10.1016/j.clbc.2017.10.005. Epub 2017 Oct 9.

PMID:
29174203
10.

FDG PET and FES PET Predict PFS on Endocrine Therapy-Response.

Kurland BF, Linden HM, Mankoff DA.

Clin Cancer Res. 2017 Jul 1;23(13):3475. doi: 10.1158/1078-0432.CCR-17-0479. No abstract available.

11.

A virtual clinical trial comparing static versus dynamic PET imaging in measuring response to breast cancer therapy.

Wangerin KA, Muzi M, Peterson LM, Linden HM, Novakova A, Mankoff DA, Kinahan PE.

Phys Med Biol. 2017 May 7;62(9):3639-3655. doi: 10.1088/1361-6560/aa6023. Epub 2017 Feb 13.

12.

Targeted lipidomics reveals activation of resolution pathways in knee osteoarthritis in humans.

Jónasdóttir HS, Brouwers H, Kwekkeboom JC, van der Linden HMJ, Huizinga T, Kloppenburg M, Toes REM, Giera M, Ioan-Facsinay A.

Osteoarthritis Cartilage. 2017 Jul;25(7):1150-1160. doi: 10.1016/j.joca.2017.01.018. Epub 2017 Feb 8.

13.

Accrual Patterns for Clinical Studies Involving Quantitative Imaging: Results of an NCI Quantitative Imaging Network (QIN) Survey.

Kurland BF, Aggarwal S, Yankeelov TE, Gerstner ER, Mountz JM, Linden HM, Jones EF, Bodeker KL, Buatti JM.

Tomography. 2016 Dec;2(4):276-282. doi: 10.18383/j.tom.2016.00169.

14.

Evaluation of Cross-Calibrated 68Ge/68Ga Phantoms for Assessing PET/CT Measurement Bias in Oncology Imaging for Single- and Multicenter Trials.

Byrd DW, Doot RK, Allberg KC, MacDonald LR, McDougald WA, Elston BF, Linden HM, Kinahan PE.

Tomography. 2016 Dec;2(4):353-360. doi: 10.18383/j.tom.2016.00205.

15.

Functional Estrogen Receptor Imaging Before Neoadjuvant Therapy for Primary Breast Cancer.

Fowler AM, Linden HM.

J Nucl Med. 2017 Apr;58(4):560-562. doi: 10.2967/jnumed.116.183533. Epub 2016 Nov 17.

16.

Patients who underwent total hip or knee arthroplasty are more physically active than the general Dutch population.

Meessen JM, Peter WF, Wolterbeek R, Cannegieter SC, Tilbury C, Bénard MR, van der Linden HM, Onstenk R, Tordoir R, Vehmeijer SB, Verdegaal SH, Vermeulen HM, Nelissen RG, Vliet Vlieland TP.

Rheumatol Int. 2017 Feb;37(2):219-227. doi: 10.1007/s00296-016-3598-9. Epub 2016 Nov 16.

17.

Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.

Kurland BF, Peterson LM, Lee JH, Schubert EK, Currin ER, Link JM, Krohn KA, Mankoff DA, Linden HM.

Clin Cancer Res. 2017 Jan 15;23(2):407-415. doi: 10.1158/1078-0432.CCR-16-0362. Epub 2016 Jun 24.

18.

Conversion from knee arthrodesis to arthroplasty: systematic review.

Kernkamp WA, Verra WC, Pijls BG, Schoones JW, van der Linden HM, Nelissen RG.

Int Orthop. 2016 Oct;40(10):2069-2074. Epub 2016 Mar 16. Review.

PMID:
26980621
19.

Temporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: 18F-Fluoroestradiol PET Imaging Shows Return of ER Expression.

Currin E, Peterson LM, Schubert EK, Link JM, Krohn KA, Livingston RB, Mankoff DA, Linden HM.

J Natl Compr Canc Netw. 2016 Feb;14(2):144-7.

20.

Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer.

Fowler AM, Clark AS, Katzenellenbogen JA, Linden HM, Dehdashti F.

J Nucl Med. 2016 Feb;57 Suppl 1:75S-80S. doi: 10.2967/jnumed.115.157933. Review.

21.

Effect of 18F-FDG uptake time on lesion detectability in PET imaging of early stage breast cancer.

Wangerin KA, Muzi M, Peterson LM, Linden HM, Novakova A, O'Sullivan F, Kurland BF, Mankoff DA, Kinahan PE.

Tomography. 2015 Sep;1(1):53-60. Erratum in: Tomography. ;2(3):238.

22.

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.

Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, Gadi VK, Guenthoer J, Beumer JH, Korde L, Strychor S, Kiesel BF, Linden HM, Thompson JA, Swisher E, Chai X, Shepherd S, Giranda V, Specht JM.

Clin Cancer Res. 2016 Jun 15;22(12):2855-64. doi: 10.1158/1078-0432.CCR-15-2137. Epub 2016 Jan 22.

23.

Quantitative Imaging in Cancer Clinical Trials.

Yankeelov TE, Mankoff DA, Schwartz LH, Lieberman FS, Buatti JM, Mountz JM, Erickson BJ, Fennessy FM, Huang W, Kalpathy-Cramer J, Wahl RL, Linden HM, Kinahan PE, Zhao B, Hylton NM, Gillies RJ, Clarke L, Nordstrom R, Rubin DL.

Clin Cancer Res. 2016 Jan 15;22(2):284-90. doi: 10.1158/1078-0432.CCR-14-3336. Review.

24.

The reason why orthopaedic surgeons perform total knee replacement: results of a randomised study using case vignettes.

Verra WC, Witteveen KQ, Maier AB, Gademan MG, van der Linden HM, Nelissen RG.

Knee Surg Sports Traumatol Arthrosc. 2016 Aug;24(8):2697-703. doi: 10.1007/s00167-015-3961-5. Epub 2016 Jan 12.

25.

Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size.

Kurland BF, Muzi M, Peterson LM, Doot RK, Wangerin KA, Mankoff DA, Linden HM, Kinahan PE.

J Nucl Med. 2016 Feb;57(2):226-30. doi: 10.2967/jnumed.115.162289. Epub 2015 Oct 22.

26.

Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.

Williams JM, Rani SD, Li X, Arlinghaus LR, Lee TC, MacDonald LR, Partridge SC, Kang H, Whisenant JG, Abramson RG, Linden HM, Kinahan PE, Yankeelov TE.

Med Phys. 2015 Jul;42(7):3801-13. doi: 10.1118/1.4921363.

27.

The Value of Establishing the Quantitative Accuracy of PET/CT Imaging.

Kinahan PE, Mankoff DA, Linden HM.

J Nucl Med. 2015 Aug;56(8):1133-4. doi: 10.2967/jnumed.115.159178. Epub 2015 Jun 18. No abstract available.

28.

Adjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is New.

Cho E, Schwemm AK, Rubinstein LM, Stevenson PA, Gooley TA, Ellis GK, Specht JM, Livingston RB, Linden HM, Gadi VK.

Clin Breast Cancer. 2015 Oct;15(5):e277-85. doi: 10.1016/j.clbc.2015.04.002. Epub 2015 Apr 24.

29.

The use of stereotactic radiosurgery for brain metastases from breast cancer: who benefits most?

Cho E, Rubinstein L, Stevenson P, Gooley T, Philips M, Halasz LM, Gensheimer MF, Linden HM, Rockhill JK, Gadi VK.

Breast Cancer Res Treat. 2015 Feb;149(3):743-9. doi: 10.1007/s10549-014-3242-x. Epub 2015 Feb 1.

30.

Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage.

Chen L, Linden HM, Anderson BO, Li CI.

Breast Cancer Res Treat. 2014 Oct;147(3):609-16. doi: 10.1007/s10549-014-3112-6. Epub 2014 Aug 28.

31.

Letter to cancer center directors: Progress in quantitative imaging as a means to predict and/or measure tumor response in cancer therapy trials.

Mountz JM, Yankeelov TE, Rubin DL, Buatti JM, Erikson BJ, Fennessy FM, Gillies RJ, Huang W, Jacobs MA, Kinahan PE, Laymon CM, Linden HM, Mankoff DA, Schwartz LH, Shim H, Wahl RL.

J Clin Oncol. 2014 Jul 1;32(19):2115-6. doi: 10.1200/JCO.2014.55.8866. Epub 2014 May 27. No abstract available.

32.

Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.

Goss PE, Hershman DL, Cheung AM, Ingle JN, Khosla S, Stearns V, Chalchal H, Rowland K, Muss HB, Linden HM, Scher J, Pritchard KI, Elliott CR, Badovinac-Crnjevic T, St Louis J, Chapman JA, Shepherd LE.

Lancet Oncol. 2014 Apr;15(4):474-82. doi: 10.1016/S1470-2045(14)70035-X. Epub 2014 Mar 11.

33.

A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC).

Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, Eary JF, Porter P, Shankar LK, Mankoff DA, Linden HM.

Mol Imaging Biol. 2014 Jun;16(3):431-40. doi: 10.1007/s11307-013-0699-7. Epub 2013 Oct 30. Erratum in: Mol Imaging Biol. 2019 Feb;21(1):191.

34.
35.

Novel methods and tracers for breast cancer imaging.

Linden HM, Dehdashti F.

Semin Nucl Med. 2013 Jul;43(4):324-9. doi: 10.1053/j.semnuclmed.2013.02.003. Review.

PMID:
23725994
36.

[Haematogenous infection of a prosthetic joint].

van der Heide HJ, van der Linden HM, Huizinga TW, Visser LG.

Ned Tijdschr Geneeskd. 2013;157(12):A5448. Review. Dutch.

PMID:
23515033
37.

An innovative care model coordinated by a physical therapist and nurse practitioner for osteoarthritis of the hip and knee in specialist care: a prospective study.

Voorn VM, Vermeulen HM, Nelissen RG, Kloppenburg M, Huizinga TW, Leijerzapf NA, Kroon HM, Vliet Vlieland TP, van der Linden HM.

Rheumatol Int. 2013 Jul;33(7):1821-8. doi: 10.1007/s00296-012-2662-3. Epub 2013 Jan 17.

PMID:
23325095
38.

Predicting Breast Cancer Endocrine Responsiveness Using Molecular Imaging.

Currin E, Linden HM, Mankoff DA.

Curr Breast Cancer Rep. 2011 Dec;3(4):205-211.

39.

Quantitative assessment of dynamic PET imaging data in cancer imaging.

Muzi M, O'Sullivan F, Mankoff DA, Doot RK, Pierce LA, Kurland BF, Linden HM, Kinahan PE.

Magn Reson Imaging. 2012 Nov;30(9):1203-15. doi: 10.1016/j.mri.2012.05.008. Epub 2012 Jul 21. Review.

40.

Early experiences in establishing a regional quantitative imaging network for PET/CT clinical trials.

Doot RK, Thompson T, Greer BE, Allberg KC, Linden HM, Mankoff DA, Kinahan PE.

Magn Reson Imaging. 2012 Nov;30(9):1291-300. doi: 10.1016/j.mri.2012.06.002. Epub 2012 Jul 15.

41.

Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients.

Kurland BF, Gadi VK, Specht JM, Allison KH, Livingston RB, Rodler ET, Peterson LM, Schubert EK, Chai X, Mankoff DA, Linden HM.

EJNMMI Res. 2012 Jun 25;2(1):34. doi: 10.1186/2191-219X-2-34.

42.

Integrated assessment techniques for linking kinematics, kinetics and muscle activation to early migration: a pilot study.

Wolterbeek N, Garling EH, van der Linden HM, Nelissen RG, Valstar ER.

Gait Posture. 2012 Jul;36(3):394-8. doi: 10.1016/j.gaitpost.2012.03.022. Epub 2012 May 1.

PMID:
22555064
43.

Kinematics of a highly congruent mobile-bearing total knee prosthesis.

Wolterbeek N, Garling EH, Mertens BJ, van der Linden HM, Nelissen RG, Valstar ER.

Knee Surg Sports Traumatol Arthrosc. 2012 Dec;20(12):2487-93. doi: 10.1007/s00167-012-1936-3. Epub 2012 Mar 17.

PMID:
22426852
44.

Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer.

Peterson LM, Kurland BF, Link JM, Schubert EK, Stekhova S, Linden HM, Mankoff DA.

Nucl Med Biol. 2011 Oct;38(7):969-78. doi: 10.1016/j.nucmedbio.2011.03.002. Epub 2011 May 5.

45.

Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.

Kurland BF, Peterson LM, Lee JH, Linden HM, Schubert EK, Dunnwald LK, Link JM, Krohn KA, Mankoff DA.

J Nucl Med. 2011 Oct;52(10):1541-9. doi: 10.2967/jnumed.111.091439. Epub 2011 Sep 8.

46.

Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.

Linden HM, Kurland BF, Peterson LM, Schubert EK, Gralow JR, Specht JM, Ellis GK, Lawton TJ, Livingston RB, Petra PH, Link JM, Krohn KA, Mankoff DA.

Clin Cancer Res. 2011 Jul 15;17(14):4799-805. doi: 10.1158/1078-0432.CCR-10-3321. Epub 2011 Jul 12.

47.

PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake.

Dunnwald LK, Doot RK, Specht JM, Gralow JR, Ellis GK, Livingston RB, Linden HM, Gadi VK, Kurland BF, Schubert EK, Muzi M, Mankoff DA.

Clin Cancer Res. 2011 Apr 15;17(8):2400-9. doi: 10.1158/1078-0432.CCR-10-2649. Epub 2011 Mar 1.

48.

Breast cancer and hormonal stimulation: is glycolysis the first sign of response?

Linden HM, Mankoff DA.

J Nucl Med. 2010 Nov;51(11):1663-4. doi: 10.2967/jnumed.110.078329. Epub 2010 Oct 18. No abstract available.

49.

Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer.

Specht JM, Kurland BF, Montgomery SK, Dunnwald LK, Doot RK, Gralow JR, Ellis GK, Linden HM, Livingston RB, Allison KH, Schubert EK, Mankoff DA.

Clin Cancer Res. 2010 May 15;16(10):2803-10. doi: 10.1158/1078-0432.CCR-10-0026. Epub 2010 May 11.

50.

Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.

Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, Doot RK, Lawton TJ, Barlow WE, Kurland BF, Schubert EK, Mankoff DA.

J Clin Oncol. 2008 Sep 20;26(27):4449-57. doi: 10.1200/JCO.2007.15.4385. Epub 2008 Jul 14.

Supplemental Content

Loading ...
Support Center